Henry Schein Inc (HSIC)vsJohnson & Johnson (JNJ)
HSIC
Henry Schein Inc
$85.83
+0.14%
HEALTHCARE · Cap: $10.00B
JNJ
Johnson & Johnson
$255.88
-3.63%
HEALTHCARE · Cap: $615.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 632% more annual revenue ($97.93B vs $13.38B). JNJ leads profitability with a 21.5% profit margin vs 3.0%. HSIC appears more attractively valued with a PEG of 1.84. JNJ earns a higher WallStSmart Score of 57/100 (C).
HSIC
Buy51
out of 100
Grade: C-
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.2%
Fair Value
$151.74
Current Price
$85.83
$65.91 discount
Intrinsic value data unavailable for JNJ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.5% earnings growth
3.0% margin — thin
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : HSIC
HSIC has a balanced fundamental profile.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bear Case : HSIC
The primary concerns for HSIC are PEG Ratio, P/E Ratio, EPS Growth. Thin 3.0% margins leave little buffer for downturns.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
HSIC profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
HSIC carries more volatility with a beta of 0.81 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 51/100), backed by strong 21.5% margins. HSIC offers better value entry with a 46.2% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Henry Schein Inc
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?